title: [A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].
abstract: A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion. A 42-year-old woman was admitted to our hospital because of right breast tumor. By physical examination, mammography, ultrasound examination and aspirated cytology, we diagnosed squamous cell carcinoma of the right breast. Before operation SCC antigen was elevated. Standard mastectomy was performed, and SCC antigen was decreased within normal range. Then, a standard regimen of chemotherapy using docetaxel with anti-hormonal therapy by LH-RH analog and tamoxifen was done as first-line adjuvant therapy. Four months after operation the SCC antigen level was elevated again, and recurrence of cancer (skin and liver metastases) was recognized. Next, we tried 5-FU/UFT plus CDDP for squamous cell carcinoma of other organs such as the esophagus. These anti-tumor drugs proved effective, and no metastasis of the skin was detected thereafter, and liver metastatic lesion was decreased in ten months. The SCC antigen level was within the normal range again. Additionally, when metastases redeveloped, TS-1 plus CDDP controlled growth of tumors in seven months. Based on the present findings,we recommend adjuvant chemotherapy by FU plus CDDP for squamous cell carcinoma of the breast.
authors.affiliation: Dept. of Surgery, Kiryu Kosei General Hospital.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: Kenji
authors.initials: K
authors.lastname: Kato
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hirata
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuba
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Hara
authors.forename: Takaaki
authors.initials: T
authors.lastname: Ito
authors.forename: Taishi
authors.initials: T
authors.lastname: Miyata
authors.forename: Takashi
authors.initials: T
authors.lastname: Akagawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kutsuna
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Machiki
authors.forename: Susumu
authors.initials: S
authors.lastname: Fujioka
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008408:Mastectomy; D009361:Neoplasm Invasiveness; D010094:Oxonic Acid / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D002945:Cisplatin; D005472:Fluorouracil